As immunotherapy moves toward personalized medicine, integrating circRNA signatures with existing biomarkers such as PD-L1 expression, tumor mutational burden, and T cell receptor repertoire may improve patient stratification and optimize therapeutic outcomes. Here, CD274 is linked to neoplasm.